Lv5
920 积分 2024-03-10 加入
CYP450 activity, drug interactions, and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors
2天前
已完结
In vitro and in vivo preclinical pharmacokinetic characterization of aficamten, a small molecule cardiac myosin inhibitor
2天前
已完结
Cardiac myosin inhibition in hypertrophic cardiomyopathy: review of the evolving evidence base
2天前
已完结
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM
2天前
已关闭
One-year functional and structural effects of mavacamten in obstructive hypertrophic cardiomyopathy: a comprehensive CMR study. Eur Heart J Cardiovasc Imaging. 2025 Sep 30;26(10):1685-1687
2天前
已关闭
Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data. Mayo Clin Proc. 2026 Feb;101(2):284-294
2天前
已关闭
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA Cardiol. 2023 Oct 1;8(10):968-977
2天前
已完结
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks. Circulation. 2023 Mar 14;147(11):850-863
2天前
已完结
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532
2天前
已完结
Effect of Aficamten on Cardiac Structure and Function in Obstructive Hypertrophic Cardiomyopathy: SEQUOIA-HCM CMR Substudy. J Am Coll Cardiol. 2024 Nov 5;84(19):1806-1817
2天前
已完结
皖公网安备34019202002308
